Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by VASSILIKI A PAPADIMITRAKOPOULOU and ANNE TSAO.
VASSILIKI A PAPADIMITRAKOPOULOU
Connection Strength
2.866
ANNE TSAO
  1. The importance of molecular profiling in predicting response to epidermal growth factor receptor family inhibitors in non-small-cell lung cancer: focus on clinical trial results. Clin Lung Cancer. 2013 Jul; 14(4):311-21.
    View in: PubMed
    Score: 0.466
  2. Mitotic inhibitors. J Thorac Oncol. 2011 Nov; 6(11 Suppl 4):S1789-90.
    View in: PubMed
    Score: 0.422
  3. The future of NSCLC: molecular profiles guiding treatment decisions. Oncology (Williston Park). 2011 Jun; 25(7):607, 614.
    View in: PubMed
    Score: 0.409
  4. Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prev Res (Phila). 2009 Nov; 2(11):931-41.
    View in: PubMed
    Score: 0.367
  5. Germline and Somatic Smoothened Mutations in Non-Small-Cell Lung Cancer Are Potentially Responsive to Hedgehog Inhibitor Vismodegib. JCO Precis Oncol. 2017 Nov; 1:1-10.
    View in: PubMed
    Score: 0.160
  6. The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2016 Oct 20; 34(30):3638-3647.
    View in: PubMed
    Score: 0.149
  7. Concordance of oral HPV prevalence between patients with oropharyngeal cancer and their partners. Infect Agent Cancer. 2016; 11:21.
    View in: PubMed
    Score: 0.144
  8. Scientific Advances in Lung Cancer 2015. J Thorac Oncol. 2016 05; 11(5):613-638.
    View in: PubMed
    Score: 0.143
  9. Immunotherapy in lung cancer. Transl Lung Cancer Res. 2014 Feb; 3(1):53-63.
    View in: PubMed
    Score: 0.123
  10. Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma. J Thorac Oncol. 2011 Dec; 6(12):2104-11.
    View in: PubMed
    Score: 0.106
  11. Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck. J Clin Oncol. 2006 Sep 01; 24(25):4163-9.
    View in: PubMed
    Score: 0.074
  12. Vidutolimod in Combination With Atezolizumab With and Without Radiation Therapy in Patients?With Programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Blockade-Resistant Advanced NSCLC. JTO Clin Res Rep. 2023 Mar; 4(3):100423.
    View in: PubMed
    Score: 0.056
  13. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. J Immunother Cancer. 2021 08; 9(8).
    View in: PubMed
    Score: 0.052
  14. The value of interventional radiology in clinical trial teams: experience from the BATTLE lung cancer trials. Clin Radiol. 2021 Feb; 76(2):155.e25-155.e34.
    View in: PubMed
    Score: 0.049
  15. Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC. J Thorac Oncol. 2020 09; 15(9):1449-1459.
    View in: PubMed
    Score: 0.048
  16. Locoregional Control, Overall Survival, and Disease-Free Survival in Stage IIIA (N2) Non-Small-Cell Lung Cancer: Analysis of Resected and Unresected Patients. Clin Lung Cancer. 2020 07; 21(4):e294-e301.
    View in: PubMed
    Score: 0.047
  17. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst. 2012 Feb 08; 104(3):228-39.
    View in: PubMed
    Score: 0.027
  18. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov. 2011 Jun; 1(1):44-53.
    View in: PubMed
    Score: 0.026
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.